Corcept Therapeutics Incorporated (CORT)

Financial leverage ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total assets	US$ in thousands	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494	412,312	367,022	328,679	320,212
Total stockholders’ equity	US$ in thousands	506,705	461,679	421,614	529,584	501,842	473,364	442,326	407,811	375,806	540,229	522,675	510,802	523,338	489,680	453,698	409,489	371,182	334,376	298,053	285,755
Financial leverage ratio		1.23	1.29	1.24	1.17	1.16	1.13	1.12	1.15	1.13	1.08	1.09	1.08	1.09	1.09	1.10	1.09	1.11	1.10	1.10	1.12

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $621,517K ÷ $506,705K
= 1.23

The financial leverage ratio of Corcept Therapeutics Inc has shown some fluctuations over the past eight quarters. The ratio peaked at 1.29 in Q3 2023, indicating a higher level of financial leverage during that period. Subsequently, in Q4 2023, the ratio decreased to 1.23, suggesting a slight reduction in financial leverage compared to the previous quarter.

Overall, the trend in the financial leverage ratio of Corcept Therapeutics Inc has been relatively stable, ranging from 1.12 to 1.29 over the analyzed period. It is important for investors and stakeholders to continue monitoring this ratio to assess the company's capital structure and risk management strategies.